The Report Covers US Diabetes Devices Companies and It is Segmented by Management Devices (insulin Pumps, Insulin Syringes, Cartridges in Reusable Pens, Insulin Disposable Pens, and Jet Injectors) and Monitoring Devices (self-Monitoring Blood Glucose and Continuous Glucose Monitoring). The Report Offers the Value (in USD) for the Above Segments.

Discover the booming US diabetes devices market, projected to reach [estimated 2033 market size in billions] by 2033, with a CAGR of 6.27%. This in-depth analysis covers market trends, key players (Abbott, Medtronic, Dexcom), and growth drivers like continuous glucose monitoring (CGM) and insulin pump advancements. Learn about market segmentation and regional insights. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

U.S. Diabetes Devices market is expected to surge $44.36 Billion by 2032, exhibiting a CAGR of 6.5% during the forecast period.

The US Diabetes Devices Market is booming, projected to reach $41.39 Billion by 2033, driven by rising diabetes prevalence and CGM innovation. This comprehensive analysis reveals market size, growth trends, key players (Abbott, Dexcom, Medtronic), and regional insights. Learn more! Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The United States Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

The Latin America Diabetes Care Devices Market report segments the industry into Monitoring Devices (Self-monitoring Blood Glucose Device, Continuous Glucose Monitoring Device), Management Devices (Insulin Pump, Insulin Syringes, Cartridges in Reusable Pens, Disposable Pens, Jet Injectors), and Geography (Brazil, Mexico, Rest of Latin America). Get five years of historical data alongside five-year market forecasts.

The US diabetes drugs and devices market is booming, projected to surpass $82 billion by 2033, driven by rising diabetes prevalence and innovative treatment advancements. Explore market trends, key players (Novo Nordisk, Medtronic, Abbott), and regional insights in this comprehensive analysis. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

The US Diabetes Devices Market size was valued at 24.62 USD Billion in 2023 and is projected to reach USD 45.51 Billion by 2031 growing at a CAGR of 6.34% from 2024 to 2031.

Key Market Drivers:

Rising Diabetes Prevalence: The escalating diabetes epidemic in the United States creates unprecedented demand for advanced diabetes management technologies. With over 37 million Americans diagnosed with diabetes and millions more at risk, the market experiences continuous growth driven by critical healthcare needs. The increasing prevalence of type 2 diabetes, particularly among younger populations, necessitates innovative device technologies that can provide comprehensive, user-friendly management solutions.

Technological Innovation in Healthcare: Rapid advancements in digital health technologies, artificial intelligence and precision medical devices drive substantial market expansion. The development of smart glucose monitoring systems, integrated insulin delivery platforms and real-time health tracking technologies creates unprecedented opportunities for comprehensive diabetes management. Cutting-edge innovations enable more personalized, precise and patient-centric approaches to diabetes care.

The US Diabetes Devices Market Size Was Worth USD 23.96 Billion in 2023 and Is Expected To Reach USD 41.88 Billion by 2032, CAGR of 6.40%.

Global Diabetes Treatment Devices Market size is expected to be worth around USD 17,599 Million by 2032 from USD 10,311 Million in 2023

The North America Diabetes Care Devices Market report segments the industry into Product (Monitoring Devices, Management Devices) and Geography (United States, Canada, Rest of North America). Get five years of historical data alongside five-year market forecasts.

The size of the US Diabetes Drugs and Devices market was valued at USD 60.12 Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 4.00">> 4.00% during the forecast period. Recent developments include: June 2023: The initial allogeneic (donor) pancreatic islet cellular therapy made from deceased donor pancreatic cells, Lantidra, has been sanctioned by the U.S. Food and Drug Administration for the management of type 1 diabetes. Lantidra is specifically authorized for adults with type 1 diabetes who are incapable of achieving target glycated hemoglobin (average blood glucose levels) due to recurrent episodes of severe hypoglycemia (low blood sugar) despite intensive diabetes management and education., January 2023: Bexagliflozin (Brenzavvy, TheracosBio) has been granted approval by the US Food and Drug Administration (FDA) for the management of type 2 diabetes in adults. This oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, taken once daily at a dosage of 20 mg, is recommended as a supplementary treatment alongside diet and exercise to enhance glycemic control specifically for individuals with type 2 diabetes, excluding those with type 1 diabetes.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period.

The Diabetes Devices Market approximate to surpass USD 67.39 billion, with a forecasted CAGR of 8.1% By 2034

The North America diabetes devices market size was valued at USD 11969.70 million in 2024 and is projected to reach from USD 12711.82 million in 2025 to USD 20568.55 million by 2033, growing at a CAGR of 6.2% during the forecast period (2025-2033).
Report Scope:

Latin America Diabetes Devices market to experience a steady at CAGR of 7.9% and USD 32.01 Billion is expected to reach at 2032.

Snapshot img

Diabetes Management Devices Market Size 2024-2028

The diabetes management devices market size is forecast to increase by USD 13.98 bn at a CAGR of 7.68% between 2023 and 2028.

The market is witnessing significant growth due to the rising global burden of diabetes and the increasing focus on advanced technologies such as artificial pancreas systems. These systems utilize insulin pumps and continuous glucose monitoring sensors to automatically adjust insulin delivery based on real-time glucose levels. Additionally, the integration of artificial intelligence and data analytics in diabetes management devices is revolutionizing the industry, enabling remote patient monitoring and personalized treatment plans. Other trends include the development of insulin pens with advanced features and the adoption of spectroscopy technology for non-invasive blood glucose monitoring. However, the prohibitive cost of diabetes care devices remains a major challenge for market growth.Overall, the market is expected to experience robust growth In the coming years, driven by technological advancements and the increasing prevalence of diabetes.

What will be the Size of the Diabetes Management Devices Market during the Forecast Period?

Request Free SampleThe market encompasses a range of technologies designed to assist individuals in managing their diabetes, including insulin delivery devices, mobile health applications, and disease management tools. With the global diabetic population projected to reach over 592 million by 2035, driven by factors such as obesity rates, smoking, and high cholesterol levels, the market for diabetes care devices is experiencing significant growth. Hospitals and specialty clinics are increasingly adopting minimally invasive devices, such as diabetes lancet devices and diabetes tracker devices, to improve patient care and outcomes. Type 1 diabetes, an autoimmune disease characterized by insulin deficiency, and Type 2 diabetes, often associated with insulin resistance, both require ongoing management to prevent complications, including kidney failure, gangrene, and lower limb amputation.Insulin delivery devices, including insulin pens and blood glucose level monitoring systems, are essential tools in managing both types of diabetes. The market for diabetes management devices is expected to continue expanding as technology advances and the global population ages.

How is this Diabetes Management Devices Industry segmented and which is the largest segment?

The diabetes management devices industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments. ProductBlood glucose monitoring devicesInsulin delivery systemsDistribution ChannelOfflineOnlineGeographyNorth AmericaUSEuropeGermanyUKFranceAsiaChinaRest of World (ROW)

By Product Insights

The blood glucose monitoring devices segment is estimated to witness significant growth during the forecast period. Diabetes management devices play a crucial role in monitoring and managing blood glucose levels for individuals with diabetes. These devices include a range of products such as insulin delivery systems, continuous monitoring systems, and glucose monitoring devices. Insulin delivery devices, including insulin pumps and pens, facilitate precise insulin administration. Continuous monitoring systems, such as continuous glucose monitoring systems (CGMs) and Mobi insulin pumps, provide real-time glucose level data through wireless transmission and dedicated apps. Glucowear, a continuous glucose monitoring system, offers non-invasive transdermal sensors and spectroscopy technology. Hospital pharmacies, retail pharmacies, and online pharmacies stock these diabetes care devices. The increasing prevalence of diabetes among the obese, elderly population, and those with conditions like high cholesterol levels, smoking, and inactive lifestyles necessitates effective diabetes management.Disease management is essential to prevent complications like kidney failure, gangrene, lower limb amputation, heart attack, blindness, and stroke. Diabetes tracker devices, such as diabetes monitoring software and artificial pancreas systems, help healthcare providers analyze glucose patterns and create treatment plans. User-friendly interfaces, visual representations, and medication adherence features enhance the efficacy of treatment. In summary, diabetes management devices, including insulin delivery devices, continuous monitoring systems, and glucose monitoring devices, are essential tools for managing diabetes and preventing complications. These devices offer precision, flexibility, and smart features, making diabetes care more accessible and convenient for individuals with diabetes. Hospital segment, diagnostic centers, diabetes clinics, and healthcare professionals uti

Diabetes Care Devices Market Outlook

According to our latest research, the global diabetes care devices market size reached USD 29.4 billion in 2024, driven by a surge in diabetes prevalence and technological advancements in care solutions. The market is growing at a robust CAGR of 7.2% and is expected to reach USD 54.7 billion by 2033. This significant growth trajectory is fueled by increasing awareness about diabetes management, rising adoption of advanced monitoring and insulin delivery devices, and supportive government initiatives worldwide. The diabetes care devices market continues to evolve rapidly, offering innovative solutions that enhance patient outcomes and improve quality of life for millions globally.

The primary growth driver for the diabetes care devices market is the escalating prevalence of diabetes worldwide. According to the International Diabetes Federation, more than 537 million adults are living with diabetes as of 2024, and this number is projected to rise steadily in the coming years. The growing burden of both Type 1 and Type 2 diabetes is prompting healthcare providers and patients to seek more effective and convenient solutions for disease management. This trend has led to a surge in demand for blood glucose monitoring devices, insulin delivery systems, and continuous glucose monitoring devices, which are critical for maintaining optimal glycemic control and reducing the risk of diabetes-related complications. Furthermore, the increasing incidence of obesity, sedentary lifestyles, and unhealthy dietary habits are further exacerbating the diabetes epidemic, thereby driving the need for advanced diabetes care devices.

Technological innovation is another crucial factor propelling the diabetes care devices market forward. The integration of digital health technologies, such as mobile applications, cloud-based data management, and wearable sensors, has revolutionized diabetes care by enabling real-time monitoring, personalized feedback, and remote patient management. Continuous glucose monitors (CGMs) and smart insulin pens, for instance, offer patients and healthcare providers valuable insights into glucose trends and insulin usage patterns, facilitating more precise and proactive diabetes management. The development of minimally invasive and non-invasive devices, along with the advent of artificial intelligence and machine learning algorithms, is further enhancing the accuracy, convenience, and user experience of diabetes care solutions. These technological advancements are not only improving clinical outcomes but also increasing patient adherence and satisfaction, thereby contributing to the sustained growth of the diabetes care devices market.

Supportive government policies and reimbursement frameworks are also playing a pivotal role in the expansion of the diabetes care devices market. Many countries are implementing national diabetes prevention and management programs, investing in public health campaigns, and increasing funding for research and innovation in diabetes care. In addition, favorable reimbursement policies for advanced diabetes devices, particularly in developed markets such as North America and Europe, are making these products more accessible to a broader patient population. Collaborations between governments, healthcare organizations, and industry stakeholders are fostering the development and adoption of cost-effective and user-friendly diabetes care solutions. As healthcare systems worldwide prioritize chronic disease management and preventive care, the demand for reliable and efficient diabetes care devices is expected to remain strong in the foreseeable future.

From a regional perspective, North America currently dominates the diabetes care devices market, accounting for the largest share of global revenues. This leadership position is attributed to the high prevalence of diabetes, well-established healthcare infrastructure, and widespread adoption of advanced medical technologies in the region. Europe follows closely, with a strong focus on diabetes research, innovation, and patient education. Meanwhile, the Asia Pacific region is emerging as a lucrative market, driven by rapid urbanization, rising disposable incomes, and increasing awareness about diabetes management. Countries such as China and India are witnessing a surge in diabetes cases, prompting significant investments in healthcare infrastructure and diabetes care solutions. Latin America and the Middle East & Africa are also experiencing steady growth, albei

The report on North America Diabetes Devices covers a summarized study of several factors supporting market growth, such as market size, market type, major regions, and end-user applications. The report enables customers to recognize key drivers that influence and govern the market.

The Latin America Diabetes Devices Market size was valued at USD 18.58 billion in 2023 and is projected to reach USD 30.87 billion by 2032, exhibiting a CAGR of 7.52 % during the forecasts period. The Latin America diabetes devices market comprises those devices that are utilized to measure and regulate diabetes such as glucose meter, insulin pump, CGM systems and insulin pen. Many of these items are used to aid in the treatment of diabetes by helping the patient to check on their blood glucose levels, give themselves insulin, and increase the control of their illness in general. Major factors that exist in the market include latest technologies like combined smartphone applications for tracking data, introduction and usage of minimally invasive CGM systems, and growth in diabetes care expenditures and knowledge of the inhabitants of the region. The market is mainly buoyed by the increasing rates of diabetes and.factor that seek to improve convenience and effectiveness of the patient. Recent developments include: In October 2023, Philips-Medisize teamed up with GlucoModicum to design and commercialize a proprietary non-invasive, wearable device that removes technology and patient-care roadblocks in continuous glucose monitoring (CGM). , In October 2022, BD signed an agreement with Biocorp intending to use connected technology to track self-monitored drug adherence and outcomes such as biologics, by using Near Field Communication (NFC) technology , In June 2022, Abbott announced the development of a Novel Continuous Gloucose-Ketone Monitoring System which is one of a kind biowearable device. the device enables diabetic people to monitor glucose and ketones continuously in one sensor only .

The U.S. Diabetes Drugs and Devices Market size was valued at USD 60.12 Billion in 2024 and is projected to reach USD 80.92 Billion by 2032, growing at a CAGR of 3.7% from 2025 to 2032.

Key Market Drivers:

• Increasing Prevalence of Diabetes: The diabetes drugs and devices market in the U.S. is driven by the increasing prevalence of the disease, with over 37.3 million Americans living with diabetes as of 2021. This demand for effective treatment options, including diabetes drugs and monitoring devices, is expected to continue, further boosting market growth, as predicted by the CDC.

• Technological Advancements in Diabetes Management: Technology advancements, such as continuous glucose monitoring (CGM) systems and insulin pumps, are revolutionizing diabetes management, driving market growth. These devices provide precise and convenient ways to manage blood sugar levels, improving quality of life and reducing complications. The American Diabetes Association (ADA) predicts continued growth in the diabetes devices market due to these technologies.